HETEROCYCLES, Vol. 95, No. 1, 2017, pp. 390-409. © 2017 The Japan Institute of Heterocyclic Chemistry Received, 18th August, 2016, Accepted, 14th October, 2016, Published online, 19th December, 2016 DOI: 10.3987/COM-16-S(S)32

EFFICIENT TOTAL SYNTHESES OF NATURAL NEOPTERIN GLYCOSIDES: NEOPTERIN GLUCRONIDE AND SOLFAPTERIN

Tadashi Hanaya,* Katsuya Iwasaki, Kaori Saeki, and Takafumi Hattori

Department of Chemistry, Faculty of Science, Okayama University, Tsushimanaka, Kita-ku, Okayama 700-8530, Japan. E-mail: hanaya@cc.okayama-u.ac.jp

This paper is dedicated to Professor Masakatsu Shibasaki on cerebration of his 70th birthday.

Abstract – 1',2'-Di-*O*-acetyl- N^2 -(*N*,*N*-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]neopterin (**11a**) and its 1',2'-di-*O*-benzoyl analog (**11b**) were prepared from neopterin in 5 steps, respectively. Glycosylation of **11a** with methyl 2,3,4-tri-*O*-benzoyl- α -D-glucopyranosyluronate bromide (**15b**) in the presence of silver triflate afforded the corresponding 3'-*O*-(β -D-glucopyranosyl)neopterin derivative (**18**) in 64% yield. The similar treatment of **11b** with 2-azido-3,4,6-tri-*O*-benzoyl-2-deoxy- α -D-glucopyranosyl)neopterin derivative (**23a**) in 58% yield. The first syntheses of neopterin glucronide (**5**) and solfapterin (**6**) were achieved by successive removal of the protecting groups of **18** and **23a**, respectively.

INTRODUCTION

Pterin glycosides having various kinds of sugars attached to the side-chain at C–6 of the pteridine ring were found to be produced by certain prokaryotes such as cyanobacteria and anaerobic photosynthetic bacteria.¹ As representative examples for glycosides of biopterin (1), 2'-*O*-(α -D-glucopyranosyl)-biopterin (2) was isolated from cyanobacterium, *Anacystis nidulans*,² *Oscillatoria* sp.,³ *Synechococcus* sp.,⁴ and *Spirulina platensis*,⁵ whereas its 2-acetamido-2-deoxy- β -D-glucopyranosyl analog (limipterin) (3) was isolated from a green sulfur photosynthetic bacterium, *Chlorobium limicola f. thiosulfatophilum* NCIB 8327.⁶ As for glycosides of neopterin (4), 3'-*O*-(β -D-glucopyranosyluronic acid)neopterin (neopterin glucronide) (5) was isolated from *Azotobactor agilis*⁷ and *Bacillus subtilis*,⁸ whereas its

2-amino-2-deoxy- α -D-glucopyranosyl analog (solfapterin) (6) was isolated from thermophilic archaebacterium *Sulfolobus solfataricus*.⁹ Various other glycosides consisting of different pterins and sugar moieties have also been found in nature.¹⁰⁻¹² However, the physiological functions of these pterin glycosides appear to have been little investigated^{13,14} in contrast to the well-documented parent pterins: *e.g.*, biopterin (1) exhibits enzyme cofactor activity in aromatic amino acid hydroxylation¹⁵ and nitric oxide synthesis¹⁶ as the form of its tetrahydro derivative, while neopterin (4) has been shown to be a marker for the activation of cellular immunity or an inducer of apoptosis.¹⁷ We have undertaken a synthetic exploration of various types of glycosides of biopterin and related pterins owing to a marked interest in their physiological functions and biological activities as well as the structural proof of those natural products.¹⁸ We give herein a full account of efficient syntheses of neopterin glucronide (5) and solfapterin (6) as the first synthetic examples of natural neopterin glycosides.¹⁹



RESULTS AND DISCUSSION

The key precursors (**11a,b**), whose pyrimidine moiety and 1',2'-hydroxy groups of the side chain are appropriately protected, were prepared starting with neopterin (**4**) (available from D-arabinose phenylhydrazone (**7**) according to the reported procedures)²⁰ (Schemes 1,2). Namely, treatment of **4** with *N*,*N*-dimethylformamide dimethyl acetal in DMF, followed by the selective 3'-*O*-protection with





tert-butyldimethylsilyl (TBS) group afforded **8**, which was then acetylated or benzoylated to give the N^2 -(N,N-dimethylaminomethylene)neopterin derivatives (**9a,b**). The N-3 position of **9a,b** was protected with 2-(4-nitrophenyl)ethyl (NPE) group²¹ by Mitsunobu reaction with 2-(4-nitrophenyl)ethanol in the presence of triphenylphosphine and diisopropyl azodicarboxylate (DIAD) to provide **10a,b**, respectively. Cleavage of 3'-O-TBS group of the 1',2'-di-O-acetylneopterin derivative (**10a**) with tetrabutylammonium fluoride resulted in the formation of the 1',3'-di-O- [**12** (47%)], 2',3'-di-O- [**13** (21%)], and 3'-O-acetate [**14** (13%)] instead of the desired 1',2'-di-O-acetate (**11a**) [Scheme 2, Table 1 (Entry 1)]. As production of **12–14** is likely to result from the 1'-O- and 2'-O-acetyl group migration by the action of 3'-alkoxide arising from the TBS cleavage, we employed acidic conditions for deprotection of 3'-O-TBS group of **10a**. Treatment of **10a** with trifluoroacetic acid (TFA) in dichloromethane exclusively provided the 1',3'-di-O-acetate (**12**), whereas hydrolysis of **10a** in 60% acetic acid predominantly gave the desired **11a** (84%), along with a minor amount of **12** (10%) (Entries 2,3). On the other hand, the same reaction of the 1',2'-di-O-benzoyl derivative (**10b**) in 60% acetic acid afforded only the desired product (**11b**) without the benzoyl migration (Entry 4).



Scheme 2

 Table 1.
 Cleavage of the 3'-O-TBS group of the neopterin derivatives (10a,b)

Entry	Substrates	Reagents, solvents	Temp, time	Products (yield)
1	10a	Bu ₄ NF, THF	rt, 30 min	11a (0%), 12 (47%), 13 (21%), 14 (13%)
2	10a	TFA, CH ₂ Cl ₂	rt, 5 h	11a (2%), 12 (90%)
3	10a	3:1:1 AcOH-H ₂ O-THF	rt, 12 h	11a (84%), 12 (10%)
4	10b	3:1:1 AcOH-H ₂ O-THF	rt, 18 h	11b (95%)

Glycosylation of **11a** with two glycosyl donors, such as methyl 2,3,4-tri-*O*-acetyl- $(15a)^{22}$ and 2,3,4-tri-*O*-benzoyl- α -D-glucopyranosyluronate bromide (15b),²³ was attempted (Scheme 3). Treatment of **11a** with 3.0 mol equiv. of **15a** in the presence of silver triflate (2.0 mol equiv.) and tetramethylurea (TMU) (1.0 mol equiv.) in dichloromethane at room temperature for 2.5 h brought about production of

the 1',2',3'-tri-*O*-acetylneopterin derivative (17) in 53% yield; the desired 3'-*O*-(β -D-glucopyranosyluronate)neopterin derivative (16) was obtained in a minor portion (31% yield).



Scheme 3

A plausible pathway for the formation of 17 from the glycosyl donor (15a) is illustrated in Scheme 4. Namely, the acyloxonium ion (A) derived from 15a reacts with the glycosyl acceptor (11a) to give the 1,2-orthoacetate intermediate (B).^{24,25} The subsequent orthoester cleavage via C would take place to afford the acetate (17).



Scheme 4

On the other hand, the similar treatment of **11a** with 3.0 mol equiv. of the 2,3,4-tri-*O*-benzoyl derivative (**15b**), provided the desired neopterin glycoside (**18**) in 64% yield, along with the recovery of **11a** (26%). Therefore the benzoyl analog (**15b**) seems to be a more suitable glycosyl donor for this work compared with the acetyl analog (**15a**). The precise ¹H-NMR parameters of **16** and **18** are summarized in Table 2 and their β -anomeric configurations were assigned by their $J_{1,2}$ values (7.3–7.9 Hz) (Table 2).

Removal of the protecting groups of the neopterin glycoside (18) was accomplished in the following manner. Attempted hydrolysis of all ester groups with aqueous sodium hydroxide resulted in the formation of an inseparable mixture of unidentified products, while selective cleavage of methyl ester of 18 with lithium iodide in refluxing pyridine,²⁶ followed by the action of sodium methoxide in methanol, afforded the 3'-O-(β -D-glucopyranosyluronic acid)neopterin derivative (19). Treatment of 19 with aqueous ammonia-methanol to remove the *N*,*N*-dimethylaminomethylene group and then with DBU in DMF to cleave the NPE group, followed by acidification using an acidic ion-exchange resin, furnished the target neopterin glucronide (5) in 83% (overall yield from 18).

Com-	Chemical shifts/6 (coupling constants/Hz)												
Pound	Pterin moiety				Me ₂ NCH=N-2		NPE-	N(3)					
	H - 7	H-1'	H-2'	H ^a -3'	H ^b -3'	Me ₂ N	CH=N	H(o)	H(m)	ArCH ₂	CH ₂ N	Other signals	
	$(J_{1',2'})$ ($(J_{2^{\prime},3^{\prime}a})$	$(J_{3'a,3'b}) (J_{3'a,3'b}) (J_{2',3'b})$				$(J_{o,m})$		$({}^{3}J_{\mathrm{H,H}})$	$(^2J_{\mathrm{H,H}})$		
16	8.78	6.11	5.59	4.28	3.79	3.24	8.87	7.43	8.14	3.15	4.57, 4.55	2.15, 2.01 (Ac) ^b	
		(5.3)	(3.2)	(11.7)	(6.5)	3.19		(8.6)		(7.7)	(12.5)		
18	8.73	6.12	5.59	4.38	3.83	3.28	8.94	7.43	8.13	3.16	4.58, 4.56	2.06, 1.77 (Ac)	
		(5.1)	(2.9)	(11.2)	(6.7)	3.21		(8.8)		(7.8)	(12.6)		
5	8.87	5.01	4.22	4.09	3.79								
		(6.4)	(3.2)	(11.0)	(6.1)								
	Glycosyl moiety												
	H-1	H-2	H-3	H-4	H-5	CO ₂ Me		Other Signals					
	$(J_{1,2})$	$(J_{2,3})$	$(J_{3,4})$	$(J_{4,5})$									
16	4.65	4.93	5.24	5.20	4.07	3.73		2.00, 1.995, 1.99 (Ac) ^b					
	(7.9)	(9.1)	(9.4)	(9.4)									
18	4.96	5.47	5.91	5.68	4.40	3.66		7.92, 7.90, 7.85 [Bz(<i>o</i>)], 7.50, 7.50, 7.44 [Bz(<i>p</i>)]					
	(7.3)	(9.0)	(9.3)	(9.3)				7.35, 7.34, 7.30 [Bz(<i>m</i>)]					
5	4.51	3.31	3.50	3.54	3.96								
	(8.1)	(9.0)	(9.1)	(9.5)									

Table 2. 600 MHz ¹H-NMR Spectral parameters for neopterin glycosides (16, 18, 5)^a

^a 16, 18 in CDCl₃, 5 in D₂O. ^b The assignments may have to be interchanged.

This successful synthesis of **5** led us to execute preparation of the other natural neopterin glycoside, solfapterin (**6**). The stereoselective formation of the β -glycosides (**16,18**) from **11a** was mainly caused by participation of the 2-*O*-acyloxy group of the glycosyl donors (**15a,b**) through the formation of an acyloxonium ion intermediate.²⁴ Accordingly, in order to avoid such a neighboring group participation in synthesis of the α -D-glucoside, solfapterin (**6**), we sought to introduce an azido group at C-2 of a glycosyl donor instead of a phthalimido group employed for preparation of limipterin (**3**).^{18b} Thus, the glycosyl donors, tri-*O*-acetyl-2-azido- α -D-glucopyranosyl bromide (**21a**)²⁷ and its tri-*O*-benzoyl analog (**21b**) were prepared from D-glucosamine hydrochloride via the 2-azido-D-glucopyranose derivatives (**20a,b**) in three steps with a slight modification of the reported procedures²⁸ (Scheme 5).



Scheme 5

Glycosylation of the neopterin derivative (11b) with glycosyl donors (21a,b) was examined under various conditions. Treatment of 11b with 3.0 mol equiv. of the acetate (21a) in the presence of silver triflate (2.0 mol equiv.) and TMU (1.0 mol equiv.) in dichloromethane at room temperature for 3 h resulted in the formation of an inseparable mixture (40:60) of the 3'-*O*-(α -D-glucopyranosyl)neopterin derivative (22a) and its β -anomer (22b) in 41% yield, along with the recovery of 11b (48%), whereas the same reaction in the absence of TMU (to improve the reactivity) at -40 °C afforded an inseparable mixture (78:22) of 22a and 22b in 78% yield. Similarly, treatment of 11b with the benzoyl analog (21b) in the presence of silver triflate at -40 °C afforded a 76:24 mixture of the neopterin glycosides (23a,b), which were then separated by column chromatography over silica gel into the desired α -D-glucopyranoside (23a) (58% yield) and the β -anomer (23b) (18%). The ¹H-NMR parameters of neopterin glycosides (22a,b, 23a,b) are listed in Table 3.

Removal of the protecting groups of the neopterin α -D-glycoside (23a) was carried out by successive treatment of 23a with sodium methoxide in methanol and then with aqueous ammonia-methanol, to give the 3-NPE-neopterin derivative (24) (Scheme 6). Removal of the NPE group of 24 with DBU in DMF, followed by acetylation for purification with column chromatography, provided the peracetylated drivative (25) in 70% (overall yield from 23a).



Scheme 6

An attempt to reduce the azido group of **25** first by treatment with triphenylphosphine-water²⁹ and the following deacetylation with aqueous ammonia afforded an inseparable mixture of the desired solfapterin (6) and its 2-acetamido derivative (**26**). Production of **26** can be perceived as the result of the subtraction of the 3-*O*-acetyl group by the aza-ylide intermediate (**D**)³⁰ arising from **25** and the subsequent hydrolysis of **E** and ammonolysis of **F** (Scheme 7).



Com-	Cher	Chemical shifts/6 (coupling constants/Hz)										
Pound	Pteri	Pterin moiety				Me ₂ NCH=N-2		NPE-N(3)				
	H - 7	H-1'	H-2'	Ha-3'	H ^b -3'	Me ₂ N	CH=N	H(o)	H(m)	ArCH ₂	CH_2N	Other signals
		$(J_{1',2'})$	$(J_{2^{\prime},3^{\prime}a})$	$(J_{3^{\prime}a,3^{\prime}b})$	$(J_{2^{\prime},3^{\prime}\mathrm{b}})$			$(J_{o,m})$		$({}^{3}J_{\mathrm{H,H}})$	$(^2J_{\mathrm{H,H}})$	
22a	8.98	6.68	6.15	4.17	4.14	3.22	8.83	7.40	8.13	3.14	4.58	8.09, 7.95 [Bz(o)]
		(5.9)	(5.3)	(11.4)	(4.1)	3.17		(8.5)		(7.8)	4.56	7.59, 7.54 [Bz(<i>p</i>)]
											(12.6)	7.45, 7.39 [Bz(<i>m</i>)]
22b	8.96	6.67	6.14	4.57	4.08	3.23	8.84	7.40	8.15	3.14	4.59	8.07, 7.95 [Bz(o)]
		(4.4)	(4.0)	(11.4)	(5.5)	3.18		(8.5)		(7.8)	4.57	7.59, 7.54 [Bz(<i>p</i>)]
											(12.5)	7.45, 7.41 [Bz(<i>m</i>)]
23a	9.05	6.81	6.24	4.38	4.19	3.20	8.83	7.35	8.11	3.12	4.55	8.09, 7.98 [Bz(o)]
		(6.2)	(4.1)	(11.4)	(3.8)	3.16		(8.5)		(7.8)	4.53	7.52, 7.51 [Bz(<i>p</i>)]
											(12.6)	7.38, 7.37 [Bz(<i>m</i>)] ^b
23b	8.87	6.71	6.24	4.68	4.24	3.23	8.85	7.46	8.13	3.14	4.60	8.05, 7.97 [Bz(o)]
		(4.1)	(4.1)	(11.7)	(5.9)	3.18		(8.8)		(7.8)	4.58	7.58, 7.52 [Bz(<i>p</i>)]
											(12.5)	7.44, 7.38 [Bz(<i>m</i>)] ^c
25	8.98	6.25	5.63	3.97	3.90	2.51 (4	AcN-2)	11.11	[H-N((3)]		2.18, 2.07 (Ac) ^d
		(4.7)	(5.0)	(11.4)	(4.7)	12.90	(NH-2)					
6	8.69	5.00	4.28	3.96	3.53							
		(6.5)	(5.0)	(10.6)	(4.4)							
6'	8.84	5.05	4.31	4.01	3.53							
		(6.8)	(4.9)	(10.6)	(4.4)							
	Glyc	osyl mo	oiety									
	H-1	Н-2	H-3	H - 4	H-5	H ^a -6	H ^b -6	Other	Signa	ls		
	$(J_{1,2})$	$(J_{2,3})$	$(J_{3,4})$	$(J_{4,5})$	$(J_{5,6a})$	$(J_{6a,6b})$	$(J_{5,6b})$					
22a	5.19	3.34	5.38	4.97	3.86	4.01	3.80	2.05,	2.00, 1	.95 (Ac))	
	(3.5)	(10.6)) (9.4)	(10.3)	(4.1)	(12.3)	(2.1)					
22b	4.55	3.45	4.97	4.97	3.75	4.21	4.07	2.04,	2.01, 1	.98 (Ac))	
	(8.2)	(10.0)) –	(10.2)	(4.4)	(12.3)	(2.0)					
23a	5.30	3.49	5.89	5.52	4.23	4.25	4.14	7.95,	7.94, 7	7.91 [Bz((<i>o</i>)], 7.495	5, 7.49, 7.48 [Bz(<i>p</i>)]
	(3.5)	(10.6)) (9.4)	(10.0)	(2.6)	(12.3)	(5.3)	7.36,	7.35, 7	7.30 [Bz($[m]^{b}$	
23b	4.98	3.75	5.57	5.49	4.23	4.55	4.35	7.93,	7.88, 7	7.82 [Bz((<i>o</i>)], 7.49,	7.47, 7.45 [Bz(<i>p</i>)]
	(7.9)	(10.3)) (9.4)	(10.0)	(3.2)	(12.0)	(5.6)	7.36,	7.29, 7	7.24 [Bz($[m]^{c}$	
25	5.01	3.29	5.09	4.98	3.95	4.27	4.05	2.05,	2.04, 2	2.01 (Ac)) ^d	
	(3.5)	(10.6)) (9.4)	(10.0)	(4.4)	(12.3)	(2.3)					
6	4.96	3.03	3.63	3.41	3.67	3.81	3.74					
	(3.5)	(10.3)) (9.4)	(9.7)	(2.1)	(12.3)	(5.0)					
6'	5.13	3.39	3.86	3.50	3.71	3.84	3.77					
	(3.5)	(10.6)) (9.4)	(9.7)	(2.1)	(12.3)	(5.3)					

Table 3.600 MHz ¹H-NMR Spectral parameters for neopterin glycosides (22a,b, 23a,b, 25, 6, 6')^a

^a **22a,b**, **23a,b**, **25** in CDCl₃, **6**, **6'** in D₂O. ^{b-d} The assignments may have to be interchanged.

We thus performed conversion of 25 to 6 in the alternative sequence: removal of all acetyl groups of 25 with aqueous ammonia and the following reduction with triphenylphosphine-water afforded solfapterin (6) in 89% yield. Treatment of 6 with an ion-exchange resin Amberlite IRA96SB(Cl⁻) furnished the corresponding hydrochloride (6') of solfapterin. The precise parameters obtained on ¹H-NMR spectra of 6 and 6' are summarized in Table 3. The spectral data of the synthetic solfapterin (6) were found to be essentially identical with those reported for natural product.⁹

The present work thus demonstrates the first syntheses of natural neopterin glycosides, neopterin glucronide (5) and solfapterin (6) by use of the key intermediates (11a,b). Extension of this work including applications of these findings in synthesizing other natural pterin glycosides and analogs is in progress.

EXPERIMENTAL

All reactions were monitored by TLC (Merck Silica gel 60 F_{254}) with an appropriate solvent system. Column chromatography was performed with Daiso Silica Gel IR-60/210w. Components were detected by exposing the plates to UV light and/or spraying them with 20% H₂SO₄-EtOH with subsequent heating. Optical rotations were measured with a JASCO P-1020 polarimeter. The ¹H NMR spectra were measured in CDCl₃ or D₂O with Varian NMR System 600 (600 MHz for ¹H, 151 Mz for ¹³C) at 23 °C. Chemical shifts are reported as δ values relative to CHCl₃ (7.26 ppm in CDCl₃) and DOH (4.79 ppm in D₂O) as an internal standard for ¹H NMR, CDCl₃ (77.0 ppm in CDCl₃) and 1,4-dioxane (67.2 ppm in D₂O) as an internal standard for ¹³C NMR. The assignments of ¹³C signals were made with the aid of 2D HSQC measurements.

1',2'-Di-*O*-acetyl-3'-*O*-(*tert*-butyldimethylsilyl)-*N*²-(*N*,*N*-dimethylaminomethylene)neopterin (9a).

To a solution of 4^{20} (1.11 g, 4.38 mmol) in DMF (15 mL) was added *N*,*N*-dimethylformamide dimethyl acetal (1.74 mL, 13.1 mmol). The mixture was stirred at rt for 3 h and concentrated in vacuo. The residue was dissolved in 5% MeOH-CHCl₃. The mixture was stirred at rt for 2 h and evaporated in vacuo. The residue was dissolved in dry pyridine (20 mL) and then *tert*-butyldimethylsilyl chloride (990 mg, 6.57 mmol) was added. The mixture was stirred at rt for 12 h (to give **8**) and then acetic anhydride (4.10 mL, 43.7 mmol) was added. The mixture was stirred at rt for 12 h, diluted with a small amount of cold water, and concentrated in vacuo. The residue was dissolved in vacuo. The residue was dissolved in CHCl₃, washed with water, dried (Na₂SO₄), and evaporated in vacuo. The residue was purified by column chromatography with 1:49 MeOH-CHCl₃ to give **9a** (1.69 g, 76% from **4**) as a yellow syrup: $R_f = 0.48$ (1:9 MeOH-CHCl₃); ¹H NMR (CDCl₃) δ –0.02, –0.01 (3H each, 2s, Me₂Si), 0.82 (9H, s, 'Bu), 1.96, 2.13 (3H each, 2s, AcO-1',2'), 3.17, 3.23 (3H each, 2s, Me₂N), 3.78 (1H, dd, $J_{3'a,3'b} = 11.6$, $J_{2',3'b} = 5.3$ Hz, H^b-3'), 3.90 (1H, dd, $J_{2',3'b} = 3.7$

Hz, H^a-3'), 5.45 (1H, td, $J_{1',2'}$ = 5.6 Hz, H-2'), 6.16 (1H, d, H-1'), 8.79 (1H, s, H-7), 8.97 (1H, s, NCH=N), 9.70 (1H, br s, H-N₍₃₎); ¹³C NMR (CDCl₃) δ –5.60, –5.53 (SiMe₂), 18.12 (<u>C</u>Me₃), 20.81, 20.85 (CO<u>C</u>H₃), 25.65 (C<u>Me₃</u>), 35.47, 41.71 (Me₂N), 61.03 (C-3'), 72.29 (C-1'), 74.26 (C-2'), 128.48 (C-4a), 147.86 (C-6), 149.55 (C-7), 156.13 (C-8a), 157.67 (C-2), 159.77 (NCH=N), 161.67 (C-4), 169.55, 169.76 (<u>C</u>OCH₃). Anal. Calcd for C₂₂H₃₄N₆O₆Si: C, 52.16; H, 6.76; N, 16.59. Found: C, 52.09; H, 6.77; N, 16.69.

1',2'-Di-*O*-benzoyl-3'-*O*-(*tert*-butyldimethylsilyl)-*N*²-(*N*,*N*-dimethylaminomethylene)neopterin (9b). The procedures similar to those for preparation of **9a** from **4** were employed. Thus, compound **4** (390 mg, 1.54 mmol) was converted into the intermediate **8**, which was then treated with benzoyl chloride (0.380 mL, 3.27 mmol) to give **9b** (721 mg, 74% yield from **4**) as a yellow foam: $R_f = 0.55$ (1:9 MeOH-CHCl₃); $[\alpha]_D^{23} - 31.2^{\circ}$ (*c* 1.20, CHCl₃); ¹H NMR (CDCl₃) δ -0.08, -0.03 (3H each, 2s, Me₂Si), 0.78 (9H, s, 'Bu), 3.14, 3.21 (3H each, 2s, Me₂N), 3.98 (1H, dd, $J_{3'a,3'b} = 11.2$, $J_{2',3'b} = 5.3$ Hz, H^b-3'), 4.11 (1H, dd, $J_{2',3'a} = 4.4$ Hz, H^a-3'), 5.93 (1H, td, $J_{1'2'} = 5.3$ Hz, H-2'), 6.59 (1H, d, H-1'), 7.39, 7.43 (2H each, 2t, $J_{o,m} = J_{m,p} = 7.6$ Hz, *m* of Bz), 7.52, 7.56 (1H each, 2tt, $J_{o,p} = 1.2$ Hz, *p* of Bz), 7.95, 8.06 (2H each, dd, *o* of Bz), 8.95 (1H, s, H-7), 8.97 (1H, s, NCH=N), 9.55 (1H, br s, H-N₍₃₎); ¹³C NMR (CDCl₃) δ = -5.60, -5.55 (SiMe₂), 18.08 (CMe₃), 25.64 (CMe₃), 35.45, 41.69 (Me₂N), 61.23 (C-3'), 73.31 (C-1'), 74.85 (C-2'), 128.43, 128.48 (*m* of Bz), 128.59 (C-4a), 129.27, 129.59 (*ipso* of Bz), 129.69, 129.89 (*o* of Bz), 133.13, 133.43 (*p* of Bz), 148.03 (C-6), 149.59 (C-7), 156.23 (C-8a), 157.66 (C-2), 159.75 (NCH=N), 161.58 (C-4), 165.17, 165.33 (COPh). Anal. Calcd for C₃₂H₃₈N₆O₆Si: C, 60.93; H, 6.07; N, 13.32. Found: C, 60.79; H, 6.16; N, 13.19.

1',2'-Di-*O*-acetyl-3'-*O*-(*tert*-butyldimethylsilyl)-*N*²-(*N*,*N*-dimethylaminomethylene)-3-[2-(4-nitro-phenyl)ethyl]neopterin (10a).

To a solution of **9a** (314 mg, 0.620 mmol), 2-(*p*-nitrophenyl)ethanol (175 mg, 1.05 mmol) and triphenylphosphine (325 mg, 1.24 mmol) in dry THF (5.0 mL) was added DIAD (1.9 M in toluene, 0.60 mL, 1.14 mmol). The mixture was stirred at rt for 7 h and then concentrated in vacuo. The residue was purified by column chromatography with 2:1 AcOEt-hexane to give **10a** (342 mg, 84%) as a pale yellow syrup: $R_f = 0.43$ (AcOEt); $[\alpha]_D^{22}$ +48.0° (*c* 1.47, CHCl₃); ¹H NMR (CDCl₃) δ 0.00, 0.03 (3H each, 2s, Me₂Si), 0.85 (9H, s, 'Bu), 1.98, 2.15 (3H each, 2s, AcO-1',2'), 3.15 (2H, t, ³*J*_{H,H} = 7.7 Hz, CH₂CH₂N), 3.21, 3.29 (3H each, 2s, Me₂N), 3.81 (1H, dd, *J*_{3'a,3'b} = 11.4, *J*_{2',3'b} = 5.4 Hz, H^b-3'), 3.90 (1H, dd, *J*_{2',3'b} = 3.9 Hz, H^a-3'), 4.57, 4.59 (2H, ²*J*_{H,H} = 12.7 Hz, CH₂N), 5.47 (1H, ddd, *J*_{1',2'} = 5.9 Hz, H-2'), 6.16 (1H, d, H-1'), 7.41 (2H, d, *J*_{0,m} = 8.7 Hz, *o* of NPE), 8.14 (2H, d, *m* of NPE), 8.82 (H-7), 8.96 (1H, s, NCH=N); ¹³C NMR (CDCl₃) δ = -5.57, -5.48 (SiMe₂), 18.15 (CMe₃), 20.84, 20.87 (CO<u>C</u>H₃), 25.68 (C<u>Me₃), 33.97</u>

(<u>C</u>H₂CH₂N), 35.68, 41.85 (Me₂N), 43.92 (CH₂N), 61.02 (C-3') 72.30 (C-1'), 74.24 (C-2'), 123.76 (*m* of NPE), 128.48 (C-4a), 129.76 (*o* of NEP), 146.36, 146.80 (*ipso*, *p* of NPE), 148.83 (C-6), 149.59 (C-7), 156.10 (C-8a), 157.16 (C-2), 159.52 (NCH=N), 160.95 (C-4), 169.58, 169.75 (<u>C</u>OCH₃). Anal. Calcd for C₃₀H₄₁N₇O₈Si: C, 54.95; H, 6.30; N, 14.95. Found: C, 54.79; H, 6.38; N, 14.78.

1',2'-Di-*O*-benzoyl-3'-*O*-(*tert*-butyldimethylsilyl)-*N*²-(*N*,*N*-dimethylaminomethylene)-3-[2-(4-nitro-phenyl)ethyl]neopterin (10b).

By use of the same procedures describe above, compound **9b** (233 mg, 0.369 mmol) was treated with 2-(*p*-nitrophenyl)ethanol (87.7 mg, 0.524 mmol), triphenylphosphine (196 mg, 0.747 mmol), and DIAD (1.9 M in toluene, 0.30 mL, 0.57 mmol) in dry THF (4.0 mL) to give **10b** (236 mg, 82%) as a pale yellow syrup: $R_f = 0.55$ (AcOEt); ¹H NMR (CDCl₃) $\delta -0.08$, -0.02 (3H each, 2s, Me₂Si), 0.78 (9H, s, 'Bu), 3.12 (2H, *t*, ³*J*_{H,H} = 7.8 Hz, CH₂CH₂N), 3.14, 3.18 (3H each, 2s, Me₂N), 4.00 (1H, dd, *J*_{3'a,3'b} = 11.5, *J*_{2',3'b} = 5.0 Hz, H^b-3'), 4.13 (1H, dd, *J*_{2',3'a} = 4.4 Hz, H^a-3'), 4.57, 4.59 (1H each, ²*J*_{H,H} = 12.8 Hz, CH₂N), 5.94 (1H, ddd, *J*_{1',2'} = 5.6 Hz, H-2'), 6.60 (1H, d, H-1'), 7.38, 7.39 (2H each, 2t, *J*_{o,m} = *J*_{m,p} = 7.8 Hz, *m* of Bz), 7.42 (2H, d, *J*_{o,m} = 8.8 Hz, *o* of NPE), 7.53, 7.58 (1H each, 2tt, *J*_{o,p} = 1.2 Hz, *p* of Bz), 7.95, 8.06 (2H each, dd, *o* of Bz), 8.12 (2H, d, *m* of NPE), 8.80 (1H, s, N-CH=N), 8.97 (1H, s, H-7); ¹³C NMR (CDCl₃) δ -5.64, -5.57 (SiMe₂), 18.04 (CMe₃), 25.61 (CMe₃), 34.03 (CH₂CH₂N), 35.38, 41.45 (Me₂N), 43.69 (CH₂N), 61.17 (C-3') 73.22 (C-1'), 74.86 (C-2'), 123.61 (*m* of NPE), 128.37, 128.45 (*m* of Bz), 129.12 (C-4a), 129.25, 129.58 (*ipso* of Bz), 129.64, 129.82 (*o* of Bz), 129.71 (*o* of NPE), 133.06, 133.37 (*p* of Bz), 146.64, 146.70 (*ipso*, *p* of NPE) 148.03 (C-6), 149.53 (C-7), 154.07 (C-8a), 157.79 (C-2), 159.13 (NCH=N), 161.48 (C-4), 165.15, 165.26 (COPh). Anal. Calcd for C₄₀H₄₅N₇O₈Si: C, 61.60; H, 5.82; N, 12.57. Found: C, 61.49; H, 5.91; N, 12.44.

1',2'-Di-*O*-acetyl-*N*²-(*N*,*N*-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]neopterin (11a) and its 1',3'-di-*O*-acetyl isomer (12).

Compound **10a** (121 mg, 0.184 mmol) was dissolved in a 3:1:1 AcOH-H₂O-THF solution (10 mL). The mixture was stirred at rt for 12 h and then concentrated in vacuo. The residue was separated by column chromatography with 1:19 MeOH-CHCl₃ to give **11a** (83.7 mg, 84%) and **12** (10.0 mg, 10%).

11a: Pale yellow syrup; $R_f = 0.55$ (1:9 MeOH-CHCl₃); $[\alpha]_D^{26} + 87.0^\circ$ (*c* 1.28, CHCl₃); ¹H NMR (CDCl₃) δ 2.02, 2.18 (3H each, 2s, AcO-1',2'), 3.15 (2H, t, ${}^{3}J_{H,H} = 7.7$ Hz, CH₂CH₂N), 3.21, 3.28 (3H each, 2s, Me₂N), 3.24 (1H, br s, HO-3'), 3.80 (1H, dd, $J_{3'a,3'b} = 12.5$, $J_{2',3a'} = 5.1$ Hz, H^b-3'), 3.91 (1H, dd, $J_{2',3'b} = 5.3$ Hz, H^a-3'), 4.56, 4.58 (1H each, 2dt, ${}^{2}J_{H,H} = 12.5$ Hz, CH₂N), 5.49 (1H, td, $J_{1',2'} = 4.2$ Hz, H-2'), 6.27 (1H, d, H-1'), 7.42 (2H, d, $J_{o,m} = 8.8$ Hz, *o* of NPE), 8.14 (2H, d, *m* of NPE), 8.82 (1H, s, 7-H), 8.92 (1H, s, NCH=N); ¹³C NMR (CDCl₃) δ 20.86, 20.89 (CO<u>C</u>H₃), 33.98 (<u>C</u>H₂CH₂N), 35.66, 41.80 (Me₂N), 43.94

(CH₂N), 60.69 (C-3') 72.95 (C-1'), 74.30 (C-2'), 123.77 (*m* of NPE), 128.19 (C-4a), 129.76 (*o* of NPE), 146.38, 146.80 (*ipso*, *p* of NPE) 147.63 (C-6), 149.49 (C-7), 153.24 (C-8a), 157.63 (C-2), 159.51 (NCH=N), 161.31 (C-4), 169.76, 170.08 (<u>C</u>OCH₃). Anal. Calcd for C₂₄H₂₇N₇O₈: C, 53.23; H, 5.03; N, 18.11. Found: C, 53.09; H, 5.20; N, 18.01.

12: Pale yellow syrup; $R_f = 0.50$ (1:9 MeOH-CHCl₃); ¹H NMR (CDCl₃) δ 2.09, 2.13 (3H each, 2s, AcO-1',3'), 3.14 (2H, t, ${}^{3}J_{H,H} = 7.5$ Hz, CH₂CH₂N), 3.20 (1H, s, HO-2'), 3.21, 3.29 (3H each, 2s, Me₂N), 4.29 (1H, dd, $J_{3'a,3'b} = 11.7$, $J_{2',3'b} = 3.7$ Hz, H^b-3'), 4.32 (1H, dd, $J_{2',3'a} = 5.4$ Hz, H^a-3'), 4.55, 4.57 (2H, 2dt, ${}^{2}J_{H,H} = 12.5$ Hz, CH₂N), 4.59 (1H, ddd, $J_{1',2'} = 7.1$ Hz, H-2'), 5.97 (1H, d, H-1'), 7.41 (2H, d, $J_{o,m} = 8.8$ Hz, *o* of NPE), 8.14 (2H, d, *m* of NPE), 8.86 (1H, s, H-7), 8.93 (1H, s, NCH=N); ¹³C NMR (CDCl₃) δ 20.83, 20.88 (COCH₃), 33.91 (CH₂CH₂N), 35.74, 41.91 (Me₂N), 44.00 (CH₂N), 64.77 (C-3') 70.40 (C-2'), 72.93 (C-1'), 123.78 (*m* of NPE), 128.24 (C-4a), 129.74 (*o* of NPE), 146.26, 146.81 (*ipso*, *p* of NPE) 149.20 (C-6), 150.48 (C-7), 152.63 (C-8a), 157.18 (C-2), 159.63 (NCH=N), 161.04 (C-4), 169.96, 171.18 (COCH₃). Anal. Calcd for C₂₄H₂₇N₇O₈: C, 53.23; H, 5.03; N, 18.11. Found: C, 53.11; H, 5.21; N, 18.25.

2',3'-Di-*O*-acetyl-*N*²-(*N*,*N*-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]neopterin (13) and its 3'- *O*-acetyl analog (14).

To a solution of **10a** (33.4 mg, 0.0509 mmol) in dry THF (0.4 mL) was added tetrabutylammonium fluoride (1.0 M THF solution, 0.065 mL, 0.065 mmol). The mixture was stirred at rt for 0.5 h and evaporated in vacuo. The residue was diluted with water and extracted with CHCl₃. The combined organic layers were dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by column chromatography with 1:19 MeOH-CHCl₃ to give a pale yellow syrup (22.1 mg) [R_f = 0.50–0.40 (1:9 MeOH-CHCl₃)], which consisted of **12** (47% yield), **13** (21%), and **14** (13%), the ratio being estimated by ¹H NMR.

13: ¹H NMR (CDCl₃) δ 1.99, 2.04 (3H each, 2s, AcO-2',3'), 3.14 (2H, t, ³*J*_{H,H} = 7.5 Hz, C<u>H</u>₂CH₂N), 3.20 (1H, s, HO-1'), 3.22, 3.29 (3H each, 2s, Me₂N), 4.27 (1H, dd, *J*_{3'a,3'b} = 12.2, *J*_{2',3'b} = 5.4 Hz, H^b-3'), 4.32 (1H, dd, *J*_{2',3'a} = 2.9 Hz, H^a-3'), 4.56, 4.58 (2H, 2dt, ²*J*_{H,H} = 12.5 Hz, CH₂N), 5.11 (1H, d, *J*_{1',2'} = 7.1 Hz, H-1'), 5.19 (1H, ddd, H-2'), 7.41 (2H, d, *J*_{o,m} = 8.8 Hz, o of NPE), 8.14 (2H, d, m of NPE), 8.87 (1H, s, H-7), 8.93 (1H, s, NCH=N).

14: ¹H NMR (CDCl₃) δ 2.09 (3H, 2s, AcO-3'), 3.16 (2H, t, ³*J*_{H,H} = 7.5 Hz, C<u>H</u>₂CH₂N), 3.22, 3.31 (3H each, 2s, Me₂N), 3.25–3.40 (2H, m, HO-1',2'), 4.12 (1H, ddd, *J*_{1',2'} = 7.1, *J*_{2',3'b} = 5.5, *J*_{2',3'a} = 3.0 Hz, H-2'), 4.34 (1H, dd, *J*_{3'a,3'b} = 12.2 Hz, H^b-3'), 4.40 (1H, dd, H^a-3'), 4.57, 4.59 (2H, 2dt, ²*J*_{H,H} = 12.5 Hz, CH₂N), 4.90 (1H, d, H-1'), 5.19 (1H, ddd, H-2'), 7.41 (2H, d, *J*_{0,m} = 8.6 Hz, *o* of NPE), 8.15 (2H, d, *m* of NPE), 8.96 (1H, s, NCH=N), 8.89 (1H, s, H-7).

1',2'-Di-O-benzoyl-N²-(N,N-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]neopterin (11b).

Compound **10b** (117 mg, 0.150 mmol) was dissolved in a 3:1:1 AcOH-H₂O-THF solution (2.0 mL). The mixture was stirred at rt for 18 h and then concentrated in vacuo. The residue was purified by column chromatography with AcOEt to give **11b** (94.9 mg, 95%) as a colorless syrup: $R_f = 0.19$ (AcOEt); $[\alpha]_D^{24} + 2.3^{\circ}$ (*c* 0.90, CHCl₃); ¹H NMR (CDCl₃) δ 3.15 (2H, t, ³*J*_{H,H} = 7.9 Hz, CH₂CH₂N), 3.19, 3.24 (3H each, 2s, Me₂N), 3.65 (1H, br s, HO-3'), 4.01 (1H, dd, $J_{3'a,3'b} = 12.3, J_{2',3'b} = 5.0$ Hz, H^b-3'), 4.14 (1H, dd, $J_{2',3'a} = 5.6$ Hz, H^a-3'), 4.57, 4.59 (1H each, 2dt, ²*J*_{H,H} = 12.5 Hz, CH₂N), 5.93 (1H, td, $J_{1',2'} = 4.1$ Hz, H-2'), 6.69 (1H, d, H-1'), 7.39, 7.44 (2H each, 2t, $J_{o,m} = J_{m,p} = 7.8$ Hz, *m* of Bz), 7.41 (2H, d, $J_{o,m} = 8.8$ Hz, *o* of NPE), 7.53, 7.58 (1H each, 2tt, $J_{a,p} = 1.2$ Hz, *p* of Bz), 7.94, 8.06 (2H each, dd, *o* of Bz), 8.14 (2H, d, *m* of NPE), 8.85 (1H, s, N-CH=N), 8.97 (1H, s, H-7); ¹³C NMR (CDCl₃) δ 34.07 (CH₂CH₂N), 35.53, 41.63 (Me₂N), 43.89 (CH₂N), 60.98 (C-3') 73.86 (C-1'), 75.13 (C-2'), 123.74 (*m* of NPE), 128.50, 128.59 (*m* of Bz), 128.64 (C-4a), 129.02, 129.38 (*ipso* of Bz), 129.74, 129.97 (*o* of Bz), 129.77 (*o* of NPE), 133.35, 133.65 (*p* of Bz), 146.61, 146.77 (*ipso*, *p* of NPE) 147.34 (C-6), 149.46 (C-7), 154.21 (C-8a), 158.05 (C-2), 159.35 (NCH=N), 161.61 (C-4), 165.60, 165.33 (COPh). Anal. Calcd for C₃₄H₃₁N₇O₈: C, 61.35; H, 4.69; N, 14.73. Found: C, 61.49; H, 4.55; N, 14.56.

1',2'-Di-O-acetyl-N²-(N,N-dimethylaminomethylene)-3'-O-(methyl2,3,4-tri-O-acetyl- α -D-gluco-pyranosyluronate)-3-[2-(4-nitrophenyl)ethyl]neopterin(16)and1',2',3'-tri-O-acetyl-N²-(N,N-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]neopterin(17).

To a solution of **11a** (34.1 mg, 0.0630 mmol), **15a**²² (75.2 mg, 0.189 mmol), and TMU (0.007 mL, 0.063 mmol) in dry CH₂Cl₂ (1.5 mL) was added siver triflate (32.4 mg, 0.126 mmol). The mixture was stirred for 2.5 h in the dark, diluted with CHCl₃, and filtered. The filtrate was washed with aqueous NaHCO₃, dried (Na₂SO₄), and evaporated in vacuo. The residue was separated by column chromatography with 1:49 MeOH-CHCl₃ to give **16** (16.6 mg, 31%) and **17** (19.4 mg, 53%).

16: Pale yellow foam; $R_f = 0.65$ (1:9 MeOH-CHCl₃); ¹H-NMR (CDCl₃), see Table 2. Anal. Calcd for C₃₇H₄₃N₇O₁₇: C, 51.81; H, 5.05; N, 11.43. Found: C, 51.69; H, 5.20; N, 11.49.

17: Pale yellow syrup; $R_f = 0.62$ (1:9 MeOH-CHCl₃); ¹H-NMR (CDCl₃) δ 1.98, 2.03, 2.16 (3H each, 3s, AcO-1',2',3'), 3.15 (2H, t, ${}^{3}J_{H,H} = 7.7$ Hz, CH₂CH₂N), 3.19, 3.58 (3H each, 2s, Me₂N), 4.30 (1H, dd, $J_{3'a,3'b} = 12.2, J_{2',3a'} = 5.9$ Hz, H^b-3'), 4.43 (1H, dd, $J_{2',3'b} = 3.2$ Hz, H^a-3'), 4.57, 4.59 (1H each, 2dt, ${}^{2}J_{H,H} = 12.5$ Hz, CH₂N), 5.65 (1H, td, $J_{1',2'} = 6.1$ Hz, H-2'), 6.17 (1H, d, H-1'), 7.41 (2H, d, $J_{o,m} = 8.8$ Hz, *o* of NPE), 8.13 (2H, d, *m* of NPE), 8.80 (1H, s, H-7), 8.88 (1H, s, NCH=N); ¹³C NMR (CDCl₃) δ 20.68, 20.72, 20.82 (COCH₃), 34.03 (CH₂CH₂N), 35.57, 41.69 (Me₂N), 43.85 (CH₂N), 61.62 (C-3') 72.95 (C-2'), 74.30 (C-1'), 123.72 (*m* of NPE), 128.93 (C-4a), 129.76 (*o* of NPE), 146.52, 146.75 (*ipso*, *p* of NPE) 147.32 (C-6), 149.18 (C-7), 153.70 (C-8a), 157.79 (C-2), 159.39 (NCH=N), 161.30 (C-4), 169.52,

169.59, 170.48 (<u>C</u>OCH₃). Anal. Calcd for C₂₂H₂₅N₇O₇: C, 52.90; H, 5.04; N, 19.63. Found: C, 53.01; H, 4.99; N, 19.52.

1',2'-Di-*O*-acetyl-*N*²-(*N*,*N*-dimethylaminomethylene)-3'-*O*-(methyl 2,3,4-tri-*O*-benzoyl-α-D-glucopyranosyluronate)-3-[2-(4-nitrophenyl)ethyl]neopterin (18).

To a solution of **11a** (46.6 mg, 0.0861 mmol), **15b**²³ (151 mg, 0.259 mmol), and TMU (0.010 mL, 0.084 mmol) in dry CH₂Cl₂ (2.0 mL) was added siver triflate (44.3 mg, 0.172 mmol). The mixture was stirred for 2.5 h in the dark, diluted with CHCl₃, and filtered. The filtrate was washed with aqueous NaHCO₃, dried (Na₂SO₄), and evaporated in vacuo. The residue was separated by column chromatography with 1:49 MeOH-CHCl₃ to give **18** (57.5 mg, 64%) and **11a** (12.1 mg, 26% recovery).

18: Pale yellow foam; $R_f = 0.55$ (1:9 MeOH-CHCl₃), 0.18 (AcOEt); $[\alpha]_D^{26} + 34.8^\circ$ (*c* 3.49, CHCl₃); ¹H NMR (CDCl₃), see Table 2. Anal. Calcd for C₅₂H₄₉N₇O₁₇: C, 59.82; H, 4.73; N, 9.39. Found: C, 59.62; H, 4.91; N, 9.16.

3'-*O*-(β-D-Glucopyranosyluronic acid)neopterin (5).

To a solution of **18** (35.1mg, 0.0336 mmol) in dry pyridine (3.0 mL) was added anhydrous lithium iodide (48.4 mg, 0.361 mmol). The mixture was refluxed for 48 h and then concentrated in vacuo. The residue was dissolved in CHCl₃, washed with 1M hydrochloric acid and then water, dried (NaSO₄), and evaporated in vacuo. The residue was dissolved in dry MeOH (2.0 mL) and then sodium methoxide (28% in MeOH, 0.0013 mL, 0.052 mmol) was added. The mixture was stirred at rt for 4 h and neutralized with Amberlite IR120(H⁺). The resin was filtered off and the filtrate was evaporated in vacuo to give **19** (20.6 mg) as a yellow syrup.

This syrup was dissolved in MeOH (2.0 mL) and then 28% aqueous ammonia solution (1.0 mL) was added. The mixture was stirred at rt for 12 h and then evaporated in vacuo. The residue was dissolved in DMF (1.5 mL) and then DBU (0.034 mL, 0.23 mmol) was added. The mixture was stirred at rt for 18 h, diluted with water, and passed through a column of Amberlite FPC3500(H⁺). The eluant was concentrated in vacuo. The residual solid was washed with CHCl₃ and dissolved in hot water. The solution was kept to stand at 0 °C overnight and the precipitate obtained by filtration was dried under reduced pressure to give **5** (12.0 mg, 83% from **18**) as an amorphous solid: $R_f = 0$ (1:9 MeOH-CHCl₃); $[\alpha]_D^{24} - 1.88^\circ$ (*c* 0.64, H₂O); ¹H NMR (D₂O), see Table 2; ¹³C NMR (D₂O) δ 71.13 (C-3'), 71.89 (C-4^{*}), 72.75 (C-1'), 73.30 (C-2'), 73.38 (C-2^{*}), 75.08 (C-5^{*}), 75.75 (C-3^{*}), 103.29 (C-1^{*}), 127.71 (C-4a), 149.49 (C-6), 150.07 (C-7), 153.00 (C-8a), 154.03 (C-2), 161.98 (C-4), 173.04 (C-6^{*}), ^{*}for glycosyl moiety. Anal. Calcd for C₁₅H₁₉N₅O₁₀: C, 41.96; H, 4.46; N, 16.31. Found: C, 41.69; H, 4.68; N, 16.15.

2-Azido-1,3,4,6-tetra-O-benzoyl-2-deoxy-α,β-D-glucopyranoses (20b).

To a solution of sodium azide (667 mg, 10.1 mmol) in pyridine (10 mL) was added triflic anhydride (1.40 mL, 8.36 mmol) at 0 °C and the mixture was stirred for 2 h. The mixture containing triflic azide was added directly to a solution of D-glucosamine hydrochloride (1.50 g, 6.96 mmol), copper sulfate (38.1 mg, 0.0696 mmol) and TEA (1.85 mL, 13.9 mmol) in pyridine (8.0 mL) and water (6.0 mL) at 0 °C. The mixture was stirred at rt for 3 h and then evaporated in vacuo. The residue was dissolved in dry pyridine (10.0 mL) and then benzoyl chloride (8.0 mL) was added at 0 °C. The mixture was stirred at rt for 12 h. After adding water, the mixture was evaporated in vacuo and the residue was purified by column chromatography with 1:3 AcOEt-hexane to give an anomeric mixture (α : β = 41:59) of **20b** (4.19 g, 97%) as a colorless syrup: R_f = 0.44 (1:3 AcOEt-hexane); ¹H NMR (CDCl₃) for α -anomer δ 4.02 (1H, dd, J_{2,3} = 10.6, J_{1,2} = 3.7 Hz, H-2), 4.43 (1H, dd, J_{6a,6b} = 12.5, J_{5,6b} = 4.3 Hz, H^b-6), 4.51 (1H, ddd, J_{4,5} = 10.0 Hz, H-5), 4.61 (1H, dd, J_{5,6a} = 2.9 Hz, H^a-6), 5.74 (1H, t, J_{3,4} = 9.8 Hz, H-4), 6.02 (1H, dd, H-3), 6.68 (1H, d, H-1), 7.35–7.55 (8H, m, *m* of Bz), 7.52–7.68 (4H, m, *p* of Bz), 7.89–8.20 (8H, m, *o* of Bz); ¹H NMR (CDCl₃) for β -anomer δ 4.13 (1H, dd, J_{6a,6b} = 12.7 Hz, H²), 4.29 (1H, ddd, J_{4,5} = 9.8, J_{5,6b} = 5.1, J_{5,6a} = 2.8 Hz, H-5), 4.46 (1H, dd, J_{6a,6b} = 12.7 Hz, H^b-6), 4.58 (1H, dd, H^a-6), 5.66–5.68 (2H, m, H-3,4), 6.04 (1H, d, H-1), 7.35–7.55 (8H, m, *m* of Bz), 7.52–7.68 (4H, m, *p* of Bz), 7.89–8.20 (8H, m, *o* of Bz).

2-Azido-3,4,6-tri-*O*-benzoyl-2-deoxy-α-D-glucopyranosyl bromide (21b).

To a solution of **20b** (1.00 g, 1.61 mmol) in CH₂Cl₂ (10.0 mL) and AcOEt (8.0 mL) was added titanium bromide (2.37 mg, 6.44 mmol) and the mixture was stirred at rt for 6 h. The mixture was diluted with CHCl₃, washed with cold water, saturated aqueous NaHCO₃, and then water. The organic layer was dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by recrystallization from AcOEt-hexane to give **21b** (801 mg, 86%) as colorless prisms: mp 142–143 °C (from AcOEt-hexane); $R_f = 0.51$ (1:3 AcOEt-hexane); $[\alpha]_D^{23}$ +109.5° (*c* 2.60, CHCl₃); ¹H NMR (CDCl₃) δ 4.01 (1H, dd, $J_{2,3} = 10.0$, $J_{1,2} = 3.8$ Hz, H-2), 4.46 (1H, dd, $J_{6a,6b} = 12.6$, $J_{5,6b} = 4.7$ Hz, H^b-6), 4.64 (1H, dd, $J_{5,6a} = 2.6$ Hz, H^a-6), 4.67 (1H, ddd, $J_{4,5} = 9.7$ Hz, H-5), 5.69 (1H, t, $J_{3,4} = 10.0$ Hz, H-4), 6.02 (1H, t, H-3), 6.55 (1H, d, H-1), 7.37, 7.38, 7.43 (2H each, 3t, $J_{o,m} = J_{m,p} = 7.8$ Hz, *m* of Bz), 7.52, 7.525, 7.56 (1H each, 3tt, $J_{o,p} = 1.2$ Hz, *p* of Bz), 7.93, 7.94, 8.03 (2H each, 3dd, *o* of Bz); ¹³C NMR (CDCl₃) δ 61.85 (C-6), 62.90 (C-2), 68.34 (C-4), 71.57 (C-3), 72.91 (C-5), 87.69 (C-1), 128.36, 128.56, 129.40 (*ipso* of Bz), 128.43, 128.47, 128.48 (*m* of Bz), 129.77, 129.83, 129.93 (*o* of Bz), 133.26, 133.58, 133.68 (*p* of Bz), 165.16, 165.33, 165.92 (<u>C</u>OPh). Anal. Calcd for C₂₇H₂₂BrN₃O₇: C, 55.87; H, 3.82; N, 7.24. Found: C, 55.90; H, 3.77; N, 7.05.

1',2'-Di-*O*-benzoyl-*N*²-(*N*,*N*-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]-3'-*O*-(3,4,6-tri-*O*-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl)neopterin (22a) and its β-anomer (22b).

A suspension of **11a** (253 mg, 0.380 mmol), silver triflate (292 mg, 1.14 mmol), and MS4A (700 mg) in dry CH₂Cl₂ (3.5 mL) was stirred at rt for 1 h in the dark and then a solution of **21a**²⁷ (450 mg, 1.14 mmol) in dry CH₂Cl₂ (2.0 mL) was added at –40 °C. After stirring at the same temp for 3 h, the mixture was diluted with CHCl₃ and filtered through celite. The filtrate was washed with saturated aqueous NaHCO₃, dried (Na₂SO₄), and evaporated in vacuo. The residue was purified by column chromatography with 1:1 AcOEt-hexane to give an inseparable mixture (290 mg), which consisted of **22a** (61% from **11b**) and **22b** (17%), the ratio being estimated by ¹H NMR: a pale yellow syrup; $R_f = 0.45$ (AcOEt), 0.51 (1:19 MeOH-CHCl₃); ¹H NMR (CDCl₃) see, Table 3. Anal. Calcd for C₄₆H₄₆N₁₀O₁₅: C, 56.44; H, 4.74; N, 14.31. Found: C, 56.28; H, 4.88; N, 14.25.

3'-*O*-(2-Azido-3,4,6-tri-*O*-benzoyl-2-deoxy-α-D-glucopyranosyl)-1',2'-di-*O*-benzoyl-*N*²-(*N*,*N*-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]neopterin (23a) and its β-anomer (23b).

A suspension of 11b (153 mg, 0.230 mmol), silver triflate (177 mg, 0.689 mmol), and MS4A (380 mg) in dry CH₂Cl₂ (1.5 mL) was stirred at rt for 1 h in the dark and then a solution of **21b** (400 mg, 0.689 mmol) in dry CH₂Cl₂ (2.0 mL) was added at -40 °C. After stirring at same temperature for 3 h, the mixture was diluted with CHCl₃ and filtered through activated carbon. The filtrate was washed with saturated aqueous NaHCO₃, dried (Na₂SO₄), and evaporated in vacuo. The residue was separated by column chromatography with 2:1 AcOEt-hexane to give 23a (155 mg, 58% from 11b) and 23b (48.1 mg, 18%). 23a: Pale yellow prisms; mp 147–148 °C (from AcOEt-hexane); $R_f = 0.61$ (AcOEt), 0.36 (3:1 AcOEt-hexane); $\left[\alpha\right]_{D}^{26}$ +32.9° (c 1.44, CHCl₃); ¹H NMR (CDCl₃), see Table 3; ¹³C NMR (CDCl₃) δ 34.04 (CH₂CH₂N), 35.44, 41.54 (Me₂N), 43.80 (CH₂N), 61.35 (C-2^{*}), 62.48 (C-6^{*}), 66.43 (C-3[']), 68.14 (C-5^{*}), 69.21 (C-4^{*}), 70.37 (C-3^{*}), 72.54, 72.59 (C-1^{*},2^{*}), 98.49 (C-1^{*}), 123.67 (*m* of NPE), 128.31, 128.35, 128.39, 128.53, 128.55 (m of Bz), 128.55, 128.70, 128.90, 129.01, 129.14, 129.52 (C-4a, ipso of Bz), 129.61, 129.71, 129.81, 129.84, 129.96, 129.96 (o of NPE, o of Bz), 133.08, 133.24, 133.42, 133.42 133.68 (p of Bz), 146.70, 146.76 (ipso, p of NPE), 147.24 (C-6), 149.96 (C-7), 154.36 (C-8a), 158.03 (C-2), 159.32 (NCH=N), 161.58 (C-4), 165.13, 165.19, 165.19, 165.35, 165.92 (COPh), *for glycosyl moiety. Anal. Calcd for C₆₁H₅₂N₁₀O₁₅: C, 62.88; H, 4.50; N, 12.02. Found: C, 62.71; H, 4.73; N, 12.20.

23b: Colorless syrup; $R_f = 0.56$ (AcOEt), 0.30 (3:1 AcOEt-hexane); $[\alpha]_D^{25} -15.6^\circ$ (*c* 1.42, CHCl₃); ¹H NMR (CDCl₃), see Table 3; ¹³C NMR (CDCl₃) δ 34.12 (<u>CH₂CH₂N</u>), 35.49, 41.57 (Me₂N), 44.03 (CH₂N), 63.10 (C-6^{*}), 64.23 (C-2^{*}), 68.81 (C-3^{*}), 69.66 (C-5^{*}), 72.00 (C-4^{*}), 72.64 (C-3^{*}), 73.35, 73.41 (C-1^{*}, 2^{*}),

102.68 (C-1^{*}), 123.74 (*m* of NPE), 128.21, 128.29, 128.36, 128.40, 128.57 (*m* of Bz), 128.73, 128.93, 128.99, 129.09, 129.41, 129.49 (C-4a, *ipso* of Bz), 129.58, 129.74, 129.78, 129.82, 129.87, 129.92 (*o* of NPE, *o* of Bz), 132.95, 133.22, 133.32, 133.32 133.58 (*p* of Bz), 146.74, 146.83 (*ipso*, *p* of NPE), 147.34 (C-6), 149.65 (C-7), 154.13 (C-8a), 158.00 (C-2), 159.31 (NCH=N), 161.61 (C-4), 165.21, 165.29, 165.45, 165.52, 165.94 (<u>C</u>OPh), ^{*}for glycosyl moiety. Anal. Calcd for C₆₁H₅₂N₁₀O₁₅: C, 62.88; H, 4.50; N, 12.02. Found: C, 62.80; H, 4.66; N, 12.22.

Tri-*N*²:1',2'-*O*-acetyl-3'-*O*-(3,4,6-tri-*O*-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl)neopterin (25).

Compound 23a (78.3 mg, 0.0672 mmol) was dissolved in dry 3:1 MeOH-CHCl₃ (1.80 mL) and sodium methoxide (28% in MeOH, 0.042 mL, 0.21 mmol) was added at 0 °C. The mixture was stirred at rt for 2 h and neutralized with Amberlite IR120(H⁺). The resin was filtered off and the filtrate was evaporated in vacuo. The residue was dissolved in MeOH (1.50 mL) and then 28% aqueous ammonia solution (1.50 mL) was added. The mixture was stirred at rt for 16 h and evaporated in vacuo. The residual syrup of 24 was dissolved in DMF (2.0 mL) and then DBU (0.062 mL, 0.41 mmol) was added. The mixture was stirred at rt for 18 h, diluted with water (3.0 mL), and neutralized with Amberlite FPC3500(H⁺). The resin was filtered off and the filtrate was evaporated in vacuo. The residue was dissolved in dry pyridine (2.0 mL) and then acetic anhydride (1.0 mL) was added at 0 °C. The mixture was stirred at rt for 16 h and evaporated in vacuo. The residue was purified by column chromatography with AcOEt to give 25 (32.5 mg, 70% from 23a) as a colorless syrup: $R_f = 0.42$ (5:95 MeOH-CHCl₃), 0.30 (AcOEt); $[\alpha]_{D^{26}}$ +130.1° (c 3.25, CHCl₃); ¹H NMR (CDCl₃), see Table 3; ¹³C NMR (CDCl₃) δ 20.54, 20.61, 20.66, 20.71, 20.79 (OCOCH₃), 25.04 (NHCOCH₃), 60.70 (C-2^{*}), 61.57 (C-6^{*}), 65.79 (C-3^{*}), 67.97 (C-5^{*}), 68.12 (C-4^{*}), 70.01 (C-3^{*}), 71.74 (C-2[']), 72.95 (C-1[']), 97.96 (C-1^{*}), 130.51 (C-4a), 149.41 (C-7), 149.69 (C-6), 154.59 (C-8a), 159.17 (C-2), 159.54 (C-4), 169.49, 169.62, 169.78, 169.78, 170.52 (OCOCH₃), 173.82 (NHCOCH₃), *for glycosyl moiety. Anal. Calcd for C₂₇H₃₂N₈O₁₄: C, 46.82; H, 4.66; N, 16.18. Found: C, 46.77; H, 4.80; N, 15.97.

3'-O-(2-Azido-2-deoxy-α-D-glucopyranosyl)neopterin (solfapterin) (6), its hydrochloride (6'), and 3'-O-(2-acetamido-2-deoxy-α-D-glucopyranosyl)neopterin (26).

A. Reduction and the following deacetylation. Compound 25 (16.2 mg, 0.0234 mmol) was dissolved in 4:1 THF-H₂O (1.00 mL) and then triphenylphosphine (12.7 mg, 0.0484 mmol) was added. The mixture was stirred at rt for 1 h and then evaporated in vacuo. The residue was dissolved in MeOH (0.40 mL) and 28% aqueous ammonia solution (0.60 mL) was added. The mixture was stirred at rt for 24 h and then evaporated in vacuo. The residue was dissolved in water and washed with CHCl₃. The aqueous layer was evaporated in vacuo to give a pale yellow syrup (9.1 mg), which consisted of 6 (72%)

from **25**) and **26** (20%), the ratio being estimated by ¹H NMR: $R_f = 0$ (1:9 MeOH-CHCl₃).

26: ¹H NMR (D₂O) δ 1.99 (3H, s, AcN-2^{*}), 3.44 (1H, t, $J_{3,4} = J_{4,5}$ Hz, H-4^{*}), 3.60–3.68 (3H, m, H-3^{*},5^{*}, H^b-3^{*}), 3.73 (1H, dd, $J_{6a,6b} = 12.3$, $J_{5,6b} = 3.9$ Hz, H^b-6^{*}), 3.80 (1H, dd, $J_{5,6a} = 2.1$ Hz, H^a-6^{*}), 3.91 (1H, dd, $J_{2,3} = 10.8$, $J_{1,2} = 3.7$ Hz, H-2^{*}), 3.94 (1H, dd, $J_{3'a,3'b} = 10.6$, $J_{2',3'a} = 4.9$ Hz, H^a-3^{*}), 4.24 (1H, dt, $J_{1',2'} = 7.2$, $J_{2',3'b} = 4.5$ Hz, H-2^{*}), 4.83 (1H, d, H-1^{*}), 4.93 (1H, d, H-1^{*}), 8.71 (1H, s, H-7), ^{*}for glycosyl moiety. **B. Deacetylation and the following reduction.** Compound **25** (21.6 mg, 0.0312 mmol) was dissolved in MeOH (0.40 mL) and 28% aqueous ammonia solution (0.60 mL) was added. The mixture was stirred at rt for 24 h and then evaporated in vacuo. The residue was dissolved in 5:1 DMF-water (0.60 mL) and then triphenylphosphine (16.1 mg, 0.0621 mmol) was added. The mixture was stirred at rt for 48 h and concentrated in vacuo. The residue was dissolved in water and washed with CHCl₃. The aqueous layer was evaporated in vacuo to give **6** (11.5 mg, 89% from **25**) as a pale yellow powder: R_f = 0 (1:9 MeOH-CHCl₃); [α]_D²³ +51.5° (*c* 0.43, H₂O); ¹H NMR (D₂O), see Table 3; ¹³C NMR (D₂O) δ 52.57 (C-2^{*}), 58.41 (C-6^{*}), 66.04 (C-3^{*}), 67.59 (C-4^{*}), 69.95 (C-2^{*}), 70.08 (C-3^{*}), 70.21 (C-5^{*}), 70.25 (C-1^{*}), 95.43 (C-1^{*}), 125.93 (C-4a), 146.24 (C-7), 147.50 (C-6), 153.37 (C-8a), 158.63 (C-2), 168.06 (C-4), ^{*}for glycosyl moiety.

Compound **6** (11.0 mg) was dissolved in water and passed through a column of Amberlite IRA96SB(Cl⁻). The eluate was evaporated in vacuo to give solfapterin hydrochloride (**6'**) (11.4 mg) as pale yellow crystals: mp 207–208 °C (dec.) (from water-EtOH); $[\alpha]_D^{23}$ +77.5° (*c* 1.12, H₂O); ¹H NMR (D₂O), see Table 3; ¹³C NMR (D₂O) δ 52.25 (C-2^{*}), 58.35 (C-6^{*}), 66.24 (C-3^{*}), 67.51 (C-4^{*}), 68.15 (C-3^{*}), 69.92 (C-2^{*}), 70.23 (C-5^{*}), 70.47 (C-1^{*}), 93.73 (C-1^{*}), 125.73 (C-4a), 147.55 (C-7), 149.55 (C-6), 152.51 (C-8a), 162.56 (C-2), 174.99 (C-4), ^{*}for glycosyl moiety. Anal. Calcd for C₁₅H₂₃ClN₆O₈: C, 39.96; H, 6.14; N, 18.64. Found: C, 39.77; H, 6.28; N, 18.51.

ACKNOWLEDGEMENTS

We are grateful to the SC-NMR Laboratory of Okayama University for the NMR measurements.

REFERENCES AND NOTES

- 1. T. Hanaya and H. Yamamoto, *IUBMB Life*, 2013, 65, 330, and references cited therein.
- 2. H. S. Forrest, C. Van Baalen, and J. Myers, Arch. Biochem. Biophys., 1958, 78, 95.
- T. Matsunaga, J. G. Burgess, N. Yamada, K. Komatsu, S. Yoshida, and Y. Wachi, *Appl. Microbiol. Biotechnol.*, 1993, **39**, 250.
- 4. Y. K. Choi, Y. K. Hwang, Y. H. Kang, and Y. S. Park, *Pteridines*, 2001, 12, 121.
- Y. Noguchi, A. Ishii, A. Matsushima, D. Haishi, K. Yasumuro, T. Moriguchi, T. Wada, Y. Kodera, M. Hiroto, H. Nishihara, M. Sekine, and Y. Inada, *Mar. Biotechnol.*, 1999, 1, 207.

- 6. K. W. Cha, W. Pfleiderer, and J. J. Yim, Helv. Chim. Acta, 1995, 78, 600.
- 7. R. Suzuki and M. Goto, J. Biochem., 1968, 63, 798.
- 8. K. Kobayashi and H. S. Forrest, Comp. Biochem. Physiol., 1970, 33, 201.
- 9. X. Lin and R. H. White, J. Bacteriol., 1988, 170, 1396.
- 10. M. Ikawa, J. J. Sasner, J. F. Haney, and T. L. Foxall, *Phytochemistry*, 1995, 38, 1229.
- 11. S.-H. Cho, J.-U. Na, H. Youn, C.-S. Hwang, C.-H. Lee, and S.-O. Kang, *Biochim. Biophys. Acta*, 1998, **1379**, 53.
- H. W. Lee, C. H. Oh, A. Geyer, W. Pfleiderer, and Y. S. Park, *Biochim. Biophys. Acta*, 1999, 1410, 61.
- Y. Wachi, S. Yoshida, K. Komatsu, and T. Matsunaga, *Jpn. Patent*, 05,286,989, 1993 (*Chem. Abstr.*, 1994, **120**, 161782t).
- T. Saito, H. Ishikawa, Y. Hada, K. Fukui, Y. Kodera, A. Matsushima, and Y. Inada, *Dyes Pigments*, 2003, 56, 203.
- (a) S. Kaufman and E. E. Kaufman, 'Folates and Pterins,' ed. by R. Blakley and S. J. Benkovic, John Wiley & Sons, New York, 1985, Vol. 2, pp. 251–352; (b) S. Kaufman and D. B. Fisher, 'Molecular Mechanisms of Oxygen Activation,' ed. by O. Hayaishi, Academic Press, New York, 1974, pp. 285–369; (c) P. F. Fitzpatrick, Annu. Rev. Biochem., 1999, 68, 355.
- (a) N. S. Kwon, C. F. Nathan, and D. J. Stuehr, *J. Biol. Chem.*, 1989, 264, 20496; (b) M. A. Marletta, *Cell*, 1994, 78, 927; (c) B. R. Crane, A. S. Arvai, D. K. Ghosh, C. Q. Wu, E. D. Getzoff, D. J. Stuehr, and J. A. Tainer, *Science*, 1998, 279, 2121.
- 17. (a) H. Wachter, E. R. Werner, G. Reibnegger, D. Fuchs, and A. Hausen, *Pteridines*, 1989, 1, 3; (b)
 A. Hausen, G. Reibnegger, B. Speck, and H. Wachter, *Transplantation*, 1984, 38, 497; (c) G. Hoffman, S. Kenn, B. Wirleitner, C. Deetjen, S. Frede, M. Smolny, J. Rieder, D. Fuchs, G. Baier-Bitterlich, and W. Schobersberger, *Immunobiology*, 1998, 199, 63.
- (a) T. Hanaya, H. Baba, H. Toyota, and H. Yamamoto, *Tetrahedron*, 2009, 65, 7989; (b) T. Hanaya, H. Baba, H. Toyota, and H. Yamamoto, *Tetrahedron*, 2008, 64, 2090; (c) T. Hanaya, H. Baba, M. Kanemoto, and H. Yamamoto, *Heterocycles*, 2008, 76, 635; (d) T. Hanaya, K. Ejiri, and H. Yamamoto, *Heterocycles*, 2012, 84, 801; (e) T. Hanaya and H. Yamamoto, *Heterocycles*, 2012, 85, 2375.
- 19. A part of the results concerning neopterin glucronide synthesis have been reported as a preliminary communication: T. Hanaya, T. Hattori, D. Takayama, and H. Yamamoto, *Pteridines*, 2010, **21**, 79.
- 20. R. Soyka and W. Pfleiderer, Helv. Chim. Acta, 1990, 73, 808.
- 21. T. Hanaya, K. Torigoe, K. Soranaka, H. Yamamoto, Q. Yao, and W. Pfleiderer, *Pteridines*, 1995, 6,
 1.

- 22. G. N. Bollenback, J. W. Long, D. G. Benjamin, and J. A. Lindquist, J. Am. Chem. Soc., 1955, 77, 3310.
- 23. W. W. Zorbach and G. D. Valiaveedan, J. Org. Chem., 1964, 29, 2462.
- 24. G. Wulff and G. Röhle, Angew. Chem., Int. Ed. Engl., 1974, 13, 157, and references cited therein.
- (a) J. Banoub and D. R. Bundle, *Can. J. Chem.*, 1979, **57**, 2091; (b) T. Hanaya, H. Baba, K. Ejiri, and H. Yamamoto, *Heterocycles*, 2010, **80**, 1013.
- 26. F. Elsinger, J. Schreiber, and A. Eschenmoser, Helv. Chim. Acta, 1960, 43, 113.
- 27. H. Paulsen, A. Richter, V. Sinnwell, and W. Stenzel, Carbohydr. Res., 1978, 64, 339.
- 28. R.-B. Yan, F. Yang, Y. Wu, L.-H. Zhang, and X.-S. Ye, Tetrahedron Lett., 2005, 46, 8993.
- 29. (a) J. D. M. Olsson and S. Oscarson, *Tetrahedron: Asymmetry*, 2009, 20, 879; (b) M. B. Soellner, B. L. Nilsson, and R. T. Raines, *J. Am. Chem. Soc.*, 2006, 128, 8820.
- 30. E. Saxon, J. I. Armstrong, and C. R. Bertozzi, Org. Lett., 2000, 2, 2141.